ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday

ADC Therapeutics (NYSE:ADCT) is projected to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $17.71 million for the quarter.

ADC Therapeutics (NYSE:ADCT) last issued its earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $19.00 million for the quarter, compared to analyst estimates of $19.01 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Trading Up 1.0 %

NYSE ADCT opened at $1.45 on Friday. The firm’s fifty day moving average price is $1.47 and its two-hundred day moving average price is $1.93. ADC Therapeutics has a 1 year low of $1.05 and a 1 year high of $5.17. The firm has a market capitalization of $143.31 million, a P/E ratio of -0.60 and a beta of 1.55.

Wall Street Analyst Weigh In

ADCT has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research note on Monday, March 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Guggenheim reduced their target price on ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 31st. Finally, Stephens increased their price target on ADC Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, ADC Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.75.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.